Not sure who's watching but OXISD has been making some waves in the biotech sector with their therapy TriKE. TriKE offers a platform to target ligands that can be incorporated and has the ability to stimulate endogenous NK cells. simply put, this process can bypass the need for cell transfers altogether and make way for a new generation of immunotherapeutics.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.